In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merrimack and Sanofi enter into antibody development deal; Merrimack regains rights

Executive Summary

Merrimack Pharmaceuticals (cancer and autoimmune diseases) has granted Sanofi-Aventis exclusive worldwide rights to develop, manufacture, and sell its Phase I monoclonal antibody MM121 for solid malignancies. Merrimack retains US co-promotion rights.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Includes Contract
    • R+D and Marketing-Licensing

Related Companies